



Malmö 31 January 2022

PRESS RELEASE

Aptahem appoints CMC Director

Aptahem (publ) announces today that Thomas Rupp has been appointed CMC Director in the company. Thomas has worked with Aptahem for several year in the role as aptamer expert, but he will now also take on the role as CMC Director. He has long and solid experience from working with aptamers and regulatory aspects, and he is considered one of the leading experts in the area in the world.

In the role as CMC Director, Thomas Rupp is responsible for the manufacturing of Apta-1 and the regulatory aspects of the manufacturing to ensure that Aptahem fulfills the regulations needed to start clinical studies. He will work in close collaboration with COO Maria Ekblad, the manufacturer LGC Biotechnologies, analytical developer AxoLabs and Recipharm, the manufacturer of the formulation.

CEO Mikael Lindstam comments:

"I am looking forward to working with Thomas in his new role. We have already worked together for some time and I have great confidence in Thomas and I know that he is the right person to be responsible for developing the final product we need for clinic. His experience and knowledge in the area of oligonucleotides, where aptamers are included, is truly valuable, and a great asset in our continued efforts in developing Apta-1 to a final product."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.